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Background
The expression of CD19 on chronic lymphocytic leuke-
mia (CLL) cells offers a novel therapy for relapsed CLL
patients (pts) previously treated with rituximab. MEDI-
551 is an affinity-optimized anti-CD19 Ab with
enhanced Ab-dependent cellular cytotoxicity (ADCC)
effector function.
Methods
Response and toxicity of single-agent MEDI-551 in multi-
ply relapsed CLL pts with prior rituximab therapy was
assessed in a phase 1/2 (ph 1/2), open-label, dose-escalation
and expansion study. Combination therapy was assessed in
an ongoing phase 2 (ph 2) study comparing MEDI-551 or
rituximab+bendamustine in relapsed/refractory CLL pts.
For the ph 1/2 study, B cell depletion was assessed with
flow cytometry and BAFF biomarker analysis; response was
assessed using the 2008 IWG criteria.
Results
In the ph 1/2 study, 26 CLL pts received ≥1 dose of
MEDI-551. In the ph 2 study, 44 pts received study drug
as of 20Mar2013. Loss of CD19 detection due to depletion
and/or occupancy with MEDI-551 was rapid and apparent
after cycle 1. B cell depletion occurred 1 day after dose 1
and was associated with increased serum BAFF concentra-
tions. In the ph 1/2 study, of 21 MEDI-551-treated CLL
pts evaluable for response, 5 achieved partial remission
and 13 had stable disease. Commonly reported adverse
events (AEs) in MEDI-551 pts were infusion-related reac-
tions (IRRs; 62%), nausea (23%), pyrexia (23%), and neu-
tropenia (23%) in the 26 ph 1/2 pts; in the 29 ph 2 pts,
they were nausea (62%), IRRs (31%), pyrexia (28%), chills
(28%), and fatigue (28%). 11 pts had ≥ grade 3 AEs in the
ph 1/2 study and 16 in the ph 2. Common treatment-
related AEs: IRRs (58%) and nausea (12%) in the ph 1/2;
nausea (52%), IRRs (28%), chills (24%), and fatigue (24%)
in the ph 2. Three treatment-unrelated AEs of general
health deterioration (ph 1/2), subarachnoid hemorrhage
(ph 1/2), and sepsis (ph 2), resulted in death.
Conclusions
MEDI-551 as a single agent demonstrated B-cell deple-
tion, increased serum BAFF levels, clinical activity, and
an acceptable risk-benefit profile in relapsed/refractory
CLL pts. Preliminary results of the ongoing ph 2 study
of MEDI-551+bendamustine demonstrated an accepta-
ble safety profile.
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